Rafael Amado
2021 - Allogene Therapeutics
In 2021, Rafael Amado earned a total compensation of $9.7M as Chief Medical Officer and Executive Vice President of Research and Development at Allogene Therapeutics, a 265% increase compared to previous year.
Compensation breakdown
Bonus | $100,000 |
---|---|
Non-Equity Incentive Plan | $228,000 |
Option Awards | $1,963,489 |
Salary | $571,591 |
Stock Awards | $6,839,951 |
Other | $11,125 |
Total | $9,714,156 |
Amado received $6.8M in stock awards, accounting for 70% of the total pay in 2021.
Amado also received $100K in bonus, $228K in non-equity incentive plan, $2M in option awards, $571.6K in salary and $11.1K in other compensation.
Rankings
In 2021, Rafael Amado's compensation ranked 1,086th out of 12,415 executives tracked by ExecPay. In other words, Amado earned more than 91.3% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,086 | 91st |
Manufacturing | 373 | 93rd |
Chemicals And Allied Products | 134 | 94th |
Drugs | 113 | 95th |
Biological Products, Except Diagnostic Substances | 31 | 93rd |
Amado's colleagues
We found four more compensation records of executives who worked with Rafael Amado at Allogene Therapeutics in 2021.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019